Press Release

23 August 2016

New Drug Discovery: Find Needles in Very Large Haystacks

Aug 23th, as the first speaker of 5th IAPC Meeting, Dr. Jin Li introduced the technical principle of DNA Encoded Library (DELs) synthesis and screening and its potential impact on the early new drug discovery, which attracted several attendees’ interest.
07 May 2016

Nature Biotechnology: DNA-encoded Drug Libraries Come of Age

May 6, 2016 – Nature Biotechnology published an article named “DNA-encoded Drug Libraries Come of Age”. In this article, it introduced the basic principles of DNA-encoded Libraries (DEL) and some major developments in innovative drug discoveries. It also gave recognition of contribution in innovative drug discoveries area made by those DEL companies at home and abroad including HitGen.
30 April 2016

Professor Richard A. Lerner and Professor K. Barry Sharpless Visit HitGen

April 29, 2016, Chengdu – HitGen had the honor to host Professor Richard A. Lerner, former President of The Scripps Research Institute and Professor K. Barry Sharpless (winner of the 2001 Nobel Prize in Chemistry for catalyzed oxidation reactions) visit our site in Chengdu. Dr. Jin Li, Chairman & CEO of HitGen, as well as department leaders showed our warm reception and hospitality to the guests. Later on, both sides held a deeper and comprehensive discussion based on companies’ technologies, development, etc.
26 April 2016

Premier Li Keqiang Speaks Highly of HitGen’s Giant “Innovative Drug

April 24, 2016 – HitGen, as a “high-tech pioneer” of biotechnology field in Sichuan Province, was inspected and encouraged by Premier Li Keqiang. The premier gave HitGen recognition on its rapid growth for the past 4 years and instructed HitGen urgently to translate the existing giant “Innovative Drug Discovery Library” to real innovative drugs that patients can use.
31 January 2016

HitGen Enters Into Research Collaboration with GBT

Chengdu, China January 8, 2016 – HitGen LtD, a privately held drug discovery company that enables the extraordinary power of DNA encoded libraries with a patented proprietary platform to discover new therapeutic starting points, announced today a research collaboration with Global Blood Therapeutics, Inc. (NASDAQ: GBT), a clinical-stage biopharmaceutical company dedicated to novel therapeutics for the treatment of grievous blood-based disorders with significant unmet needs. HitGen will provide biology, chemistry, and screening to support GBT’s efforts around an undisclosed novel target.
04 June 2015

Drug Discovery Deal Signed between HitGen and Tasly

Recently, Tasly Holding Group (Tasly, a major pharmaceutical company in China) held “Industry- Research-Investment Collaboration Signing Ceremony for its Big Health Project” in TianJin, China. In the event, Tasly signed 11 new drug discovery collaboration agreements with HitGen Ltd.(HitGen) and other 8 companies, research institutions. According to the agreement, HitGen will use its proprietary DNA Encoded Libraries to collaborate with Tasly. The collaboration has significant financial value.
17 April 2015

HitGen Announces Collaboration in Drug Discovery with Cyclofluidic Ltd

Chengdu, China, 17 April 2015– HitGen Ltd today announced that it has entered into research collaboration with Cyclofluidic Ltd, UK, using hits obtained from HitGen’s proprietary lead discovery technology. Within the framework of the collaboration, novel allosteric inhibitors of GSK3b, a kinase implicated in neurodegenerative diseases, will be optimised using CyclOpsTM technology to provide advanced leads suitable for clinical development.
10 November 2013

HitGen Announces Collaboration with the University of Manchester

Chengdu, November 8th, 2013 – HitGen Ltd today announced that it has entered into a research collaboration with The University of Manchester’s Cancer Research UK Manchester Institute Drug Discovery Group and Cancer Research Technology using HitGen’s proprietary lead discovery technology. Within the framework of the collaboration, hundreds of millions of small molecules will be screened to discover and advance drug candidates against multiple new oncology targets of interest to the Cancer Research UK Manchester Institute.
04 June 2012

HitGen signing agreement with CDHT

Dr Jin Li (Chairman and Chief Executive Officer) signed an agreement with the Chengdu Hi-tech Zone to base HitGen there. CDHT is one of the earliest state-level hi-tech industrial development zones, sponsored by the Chinese Ministry of Science and Technology.

News

Press Release

Thanks for reading!